Preventive Vaccines Market, By Vaccine Type (Live/Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines, and Others), By Disease Type (Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, and Others), By Distribution Channel (Public and Private), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Published In : Apr 2024

Code : CMI5342

Pages :173

Formats :

Excel and PDF

Industry : Pharmaceutical

Key Developments

In October 2023, Serum Institute of India Pvt. Ltd., a biotechnology company, and Mylab Discovery Solutions, announced that they had launched Nasovac S4, a needle free nasal influenza vaccine in India. The vaccine contains four influenza vaccine strains and it is recommended for individuals above the age of 2 years.
In July 2023, Merck & Co., Inc., a global pharmaceutical company, announced the positive topline results from two Phase 3 trials evaluating V116, 21-valent pneumococcal conjugate vaccine specifically designed for adults. The 21 serotypes covered by V116 are responsible for 85% of invasive pneumococcal disease in individuals 65 and older. V116 is an investigational, 21-valent pneumococcal conjugate vaccine in Phase 3 development for the prevention of invasive pneumococcal disease and pneumococcal pneumonia in the adult population.
In June 2023, Sanofi, a healthcare company, announced positive results from its Phase II clinical trials in infants of its 21-valent pneumococcal conjugate vaccine candidate, GBP410 (SP0202). GBP410 (SP0202), jointly developed by SK bioscience, a biotechnology company, and Sanofi, is a pneumococcal conjugate vaccine that combines specific proteins with the polysaccharide capsule of Streptococcus pneumoniae.
In May 2023, Pfizer India, a pharmaceutical company, announced a partnership with Apollo Hospital, a multi-specialty hospital chain based in India, to build Centre of Excellence (CoE) for adult vaccination. The aim of this partnership is to increase the adoption of adult vaccination by creating an end-to-end ecosystem within the hospital to protect patients against vaccine preventable diseases. The center will immunize against various vaccine preventable diseases such as pneumococcal diseases, Hepatities A, and others.
In April 2023, the U.A.E Ministry of Health and Prevention (MoHAP) participated in the global celebration of World Immunization Week, which had the theme, "The Big Catch Up," by launching a vaccine awareness campaign in coordination with health authorities. The campaign, which is an annual event, included educational activities, scientific seminars, and innovative awareness lectures aimed at highlighting the importance of vaccination, increasing demand for immunization services and emphasizing the importance of completing vaccines and doses prescribed in the National Immunization Programme.